Frederick W. Alt received the 2015 Szent-Gy?rgi Prize forProgress inCancer Research
10.1186/s40880-015-0075-x
- Author:
PeterScully
;
JieZhao
;
SujuanBa
- Keywords:
The National Foundation for Cancer Research;
The Szent-Gy?rgyi Prize;
Frederick Alt;
Gene ampliifcation;
Non-homologous end joining
- From:Chinese Journal of Cancer
2016;35(3):101-104
- CountryChina
- Language:Chinese
-
Abstract:
The Szent-Gy?rgyi Prize for Progress in Cancer Research is a prestigious scientiifc award established by the National Foundation for Cancer Research (NFCR)—a leading cancer research charitable organization in the United States that is committed to supporting scientiifc research and public education relating to the prevention, early diagnosis, better treatments, and ultimately, a cure for cancer. Each year, the Szent-Gy?rgyi Prize honors an outstanding researcher, nominated by colleagues or peers, who has contributed outstanding, signiifcant research to the ifght against cancer, and whose accomplishments have helped improve treatment options for cancer patients. The Prize also promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. This report highlights the pio-neering work led by the 2015 Prize winner, Dr. Frederick Alt. Dr. Alt’s work in the area of cancer genetics over four decades has helped to shape the very roots of modern cancer research. His work continues to profoundly impact the approaches that doctors around the globe use to diagnose and treat cancer. In particular, his seminal discoveries of gene ampliifcation and his pioneering work on molecular mechanisms of DNA damage repair have helped to usher in the era of genetically targeted therapy and personalized medicine.
